Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Small cap blues

4Q Stock Wrap-Up

Small cap blues

While investors were hoping for some upward momentum going into the new year, the BioCentury 100 index shed 1% in 4Q07 amid a turbulent broader market that was driven by economic concerns. Small caps were particularly hard-hit, with companies valued under $500 million taking double-digit losses (see "Results by Market Cap").

Nevertheless, the BioCentury benchmark managed to close the year up 12%, built on gains in the second and third

Read the full 752 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers